A detailed history of Israel Englander (Millennium Management LLC) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 75,674 shares of NTLA stock, worth $1.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75,674
Previous 178,879 57.7%
Holding current value
$1.22 Million
Previous $4.92 Million 65.59%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$20.02 - $27.22 $2.07 Million - $2.81 Million
-103,205 Reduced 57.7%
75,674 $1.69 Million
Q1 2024

May 15, 2024

BUY
$23.82 - $32.8 $4.26 Million - $5.87 Million
178,879 New
178,879 $4.92 Million
Q2 2023

Aug 14, 2023

SELL
$34.58 - $46.03 $5.17 Million - $6.88 Million
-149,508 Reduced 49.84%
150,482 $6.14 Million
Q1 2023

May 15, 2023

BUY
$33.3 - $44.82 $8.32 Million - $11.2 Million
249,869 Added 498.53%
299,990 $11.2 Million
Q4 2022

Feb 14, 2023

SELL
$33.21 - $62.69 $9.31 Million - $17.6 Million
-280,321 Reduced 84.83%
50,121 $1.75 Million
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $1.56 Million - $2.08 Million
-28,947 Reduced 8.05%
330,442 $18.5 Million
Q2 2022

Aug 15, 2022

SELL
$38.49 - $76.21 $5.42 Million - $10.7 Million
-140,877 Reduced 28.16%
359,389 $18.6 Million
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $28.5 Million - $58.3 Million
489,645 Added 4610.16%
500,266 $36.4 Million
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $9.23 Million - $12.7 Million
-91,646 Reduced 89.61%
10,621 $1.26 Million
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $9.93 Million - $13.3 Million
-74,983 Reduced 42.3%
102,267 $13.7 Million
Q2 2021

Aug 16, 2021

SELL
$60.88 - $161.91 $15.4 Million - $40.9 Million
-252,476 Reduced 58.75%
177,250 $28.7 Million
Q1 2021

May 17, 2021

BUY
$46.59 - $83.68 $4.71 Million - $8.46 Million
101,087 Added 30.76%
429,726 $34.5 Million
Q4 2020

Feb 16, 2021

SELL
$18.83 - $63.53 $2.57 Million - $8.66 Million
-136,280 Reduced 29.31%
328,639 $17.9 Million
Q3 2020

Nov 16, 2020

BUY
$17.47 - $24.93 $5.74 Million - $8.19 Million
328,494 Added 240.79%
464,919 $9.24 Million
Q2 2020

Aug 14, 2020

BUY
$11.14 - $22.87 $1.52 Million - $3.12 Million
136,425 New
136,425 $2.87 Million
Q1 2020

May 14, 2020

SELL
$9.44 - $15.58 $159,300 - $262,912
-16,875 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$10.43 - $17.67 $30,789 - $52,161
-2,952 Reduced 14.89%
16,875 $248,000
Q3 2019

Nov 14, 2019

SELL
$13.07 - $18.51 $2.81 Million - $3.98 Million
-215,190 Reduced 91.56%
19,827 $264,000
Q2 2019

Aug 15, 2019

SELL
$13.88 - $18.41 $79.9 Million - $106 Million
-5,757,263 Reduced 96.08%
235,017 $3.85 Million
Q2 2019

Aug 14, 2019

BUY
$13.88 - $18.41 $82.4 Million - $109 Million
5,937,362 Added 10811.32%
5,992,280 $69 Million
Q1 2019

May 14, 2019

SELL
$12.79 - $17.62 $18,379 - $25,319
-1,437 Reduced 2.55%
54,918 $938,000
Q4 2018

Feb 14, 2019

BUY
$11.39 - $27.13 $641,883 - $1.53 Million
56,355 New
56,355 $769,000
Q1 2018

May 15, 2018

SELL
$19.43 - $34.95 $690,600 - $1.24 Million
-35,543 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$17.39 - $31.12 $618,092 - $1.11 Million
35,543
35,543 $683,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.22B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.